CGMs are wearables that help measure blood sugar and can be used with insulin pumps. Dexcom, a CGM manufacturer based in San Diego, said it analyzed Optum insurance claims and found CGM use doubled among patients with insulin regimens after they began taking a GLP-1 drug. For patients that use basal insulin or non-insulin therapies, CGM use nearly quadrupled after taking GLP-1s.
Dexcom said its findings are in contrast to industry concerns that GLP-1 drugs may lead to less usage of diabetes monitoring products.